DNA Methylation Biomarkers Predict Offspring Metabolic Risk From Mothers With Hyperglycemia in Pregnancy

Area of Science:

• Endocrinology and Metabolism
• Epigenetics
• Perinatal Medicine

Background:

• Maternal hyperglycemia during pregnancy is a known risk factor for adverse offspring metabolic health.
• Existing predictive models for offspring metabolic dysfunction often rely solely on clinical factors.
• The role of epigenetic modifications in mediating the effects of in utero exposures on long-term metabolic health requires further elucidation.

Purpose of the Study:

• To identify cord blood DNA methylation biomarkers associated with maternal hyperglycemia.
• To evaluate the predictive value of these biomarkers for offspring metabolic dysfunction, specifically beta-cell dysfunction.
• To investigate the functional impact of hyperglycemia on DNA methylation and gene expression in relevant human cells.

Main Methods:

• Analysis of cord blood DNA methylation profiles in relation to maternal glycemic status.
• Statistical modeling to assess the predictive accuracy of methylation biomarkers for offspring beta-cell dysfunction at various ages.
• Validation studies using human beta-cells and pancreatic ductal epithelial cells to confirm hyperglycemia's effect on methylation-dependent gene expression.

Main Results:

• Nineteen cord blood DNA methylation biomarkers were identified and linked to maternal hyperglycemia.
• These biomarkers significantly improved the prediction of offspring beta-cell dysfunction at ages 7, 11, and 18, outperforming clinical factors alone.
• In vitro studies confirmed that maternal hyperglycemia influences methylation-dependent gene expression in human beta-cells and pancreatic ductal epithelial cells.

Conclusions:

• Cord blood DNA methylation biomarkers associated with maternal hyperglycemia serve as early indicators of offspring metabolic dysfunction.
• Epigenetic modifications at birth, influenced by the in utero environment, play a crucial role in mediating long-term metabolic health outcomes.
• These findings underscore the potential for epigenetic biomarkers in early diabetes risk assessment and intervention strategies.